Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAXYNERGY: Early Switch of Taxanes in mCRPC
NCT01718353Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2013
- Primary completion
- Aug 2015
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cabazitaxel ginsenoside liposome injection, docetaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sanofi. Started Mar 2013; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injectiondocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01718353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01718353.